Abstract: An apparatus for building a deep learning model for image learning includes a first deep learning model configured to obtain a first spatial feature map and a first heatmap including center information of an object belonging to an image by learning the image. The apparatus also includes a second deep learning model configured to perform imitation learning on the first deep learning model. The second deep learning model may obtain a second spatial feature map by learning the image and perform learning such that the second spatial feature map imitates the first spatial feature map. The second deep learning model may also obtain a second heatmap including a center of the object and perform learning such that the second heatmap imitates the first heatmap.

Abstract: A cell assembly manufacturing device includes an alignment unit including a guide jig configured to align a position of a battery cell; an attachment unit configured to attach a flame spread prevention sheet to the battery cell; a sensor module configured to sense a position of the guide jig and a position of the flame spread prevention sheet; and a processor configured to inspect an attachment position of the flame spread prevention sheet, based on the position of the guide jig and the position of the flame spread prevention sheet sensed by the sensor module.

Abstract: A flame-retardant sheet attaching device is disclosed. The flame-retardant sheet attaching device may include a first pressurizing device configured to move in a first direction and apply pressure to a flame-retardant sheet, and a second pressurizing device configured to move in the first direction, the second pressurizing device having at least a portion inserted into a groove of the flame-retardant sheet. The flame-retardant sheet may be configured to move, based on the movement of the second pressurizing device, in a second direction, perpendicular to the first direction. The first pressurizing device may be configured to restrict the movement of the flame-retardant sheet in the first direction, when the flame-retardant sheet moves in the second direction.

Abstract: The present invention provides an antibacterial composition including two or more strains selected from the group consisting of Anaerostipes hadrus, Collinsella aerofaciens, Blautia wexlerae and Bifidobacterium longum strains that inhibit the activity of antibiotic-resistant bacteria.

Abstract: A method and a system thereof for producing a digital holographic screen based on multi-hogel printing are proposed. The system includes a light source unit including lasers, a dichroic mirror for RGB three color matching, mirrors, a beam splitter, and an optical shutter, an object beam unit including a spatial filter, a lens, and a mirror, a reference beam unit including a spatial filter, a lens, and a mirror, a diffuser fixing unit including a diffuser holder and a diffuser positioned between the object beam unit and a recording material and configured to scatter and diffuse the object beam, a photomask movement unit including a photomask holder, an XY-translation stage, and a photomask positioned between the reference beam unit and the recording medium and on which a grid-shaped on/off binary pattern is printed, and a controller configured to control the optical shutter and the XY-translation stage.

Abstract: The invention provides compounds of formulae A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: Discussed is a display device including a display panel, first gate lines located on the display panel, second gate lines separated from the first gate lines and located on the display panel, first data lines provided on the display panel corresponding to a first display area to cross the first gate lines and defining first pixel areas configuring the first display area, second data lines provided on the display panel corresponding to a second display area to cross the second gate lines and second pixel areas configuring the second display area, wherein the first pixel areas and the second pixel areas have the same size, and wherein a separation area is interposed between the first gate lines and the second gate lines, and a width of the separation area is equal to or wider than a width of a thin film transistor.

Abstract: A user wears a virtual reality mask (VR mask) (100) and then watches a virtual reality image. The VR mask (100) blocks light incident from the outside. When the user wears the VR mask (100), the user cannot discover an obstacle (500) positioned outside the VR mask (100). The user may collide with the obstacle (500) and may be injured by the obstacle (500). Accordingly, in order to prevent injury to the user who uses the VR mask (100), it is necessary to make the user recognize the obstacle (500) positioned outside the VR mask (100). In order to recognize an obstacle, a virtual reality image and the obstacle may be displayed together, or the amount of light incident from the outside may be adjusted.

Abstract: A user wears a virtual reality mask (VR mask) (100) and then watches a virtual reality image. The VR mask (100) blocks light incident from the outside. When the user wears the VR mask (100), the user cannot discover an obstacle (500) positioned outside the VR mask (100). The user may collide with the obstacle (500) and may be injured by the obstacle (500). Accordingly, in order to prevent injury to the user who uses the VR mask (100), it is necessary to make the user recognize the obstacle (500) positioned outside the VR mask (100). In order to recognize an obstacle, a virtual reality image and the obstacle may be displayed together, or the amount of light incident from the outside may be adjusted.

Abstract: The invention provides compounds of formulae A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: Discussed is a display device including a display panel, first gate lines located on the display panel, second gate lines separated from the first gate lines and located on the display panel, first data lines provided on the display panel corresponding to a first display area to cross the first gate lines and defining first pixel areas configuring the first display area, second data lines provided on the display panel corresponding to a second display area to cross the second gate lines and second pixel areas configuring the second display area, wherein the first pixel areas and the second pixel areas have the same size, and wherein a separation area is interposed between the first gate lines and the second gate lines, and a width of the separation area is equal to or wider than a width of a thin film transistor.

Abstract: A display device in one embodiment includes a display panel configured to display an image in first and second display areas, a plurality of first gate lines corresponding to the first display area, and a plurality of second gate lines separated from the first gate lines and corresponding to the second display area. Accordingly, the distance between the first gate lines of the first display area and the second gate lines of the second display area is maximized to prevent static electricity from occurring between the electrodes, thereby increasing product yield.

Abstract: The invention provides heterocyclic compounds of formula A, B, and C as described herein that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: We describe the use of comparative structural analysis and structure-guided molecular design to develop potent and selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13). We applied a three-step process, starting with a comparative analysis of the X-ray crystallographic structure of compound 5 in complex with MMP-13 with published structures of known MMP-13 inhibitor complexes followed by molecular design and synthesis of potent, but non-selective zinc-chelating MMP inhibitors (e.g., 10a and 10b). After demonstrating that the pharmacophores of the chelating inhibitors (S)-10a, (R)-10a, and 10b were binding within the MMP-13 active site, the Zn2+ chelating unit was replaced with non-chelating polar residues that bridged over the Zn2+ binding site and reach into a solvent accessible area.

Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: A display device in one embodiment includes a display panel configured to display an image in first and second display areas, a plurality of first gate lines corresponding to the first display area, and a plurality of second gate lines separated from the first gate lines and corresponding to the second display area. Accordingly, the distance between the first gate lines of the first display area and the second gate lines of the second display area is maximized to prevent static electricity from occurring between the electrodes, thereby increasing product yield.

Abstract: The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.

Abstract: A user interface method for a terminal for a vehicle is provided. The terminal obtains position information to detect a point of a road. A road image of a driving direction is obtained, a lanes of the road represented on the obtained road image is recognized, and a point of a road and lane in which the vehicle having the terminal arranged therein is detected. A virtual road image regarding the recognized lanes is generated, and the generated virtual lanes are added to the road image of the driving direction of the vehicle, and displayed. Traffic information for each lane and surrounding information (i.e. lane closure, construction, accident, etc.,) at the detected point of the relevant road are obtained, and the obtained information is displayed for each virtual lane.

Abstract: A user interface method for a terminal for a vehicle is provided. The terminal obtains position information to detect a point of a road. A road image of a driving direction is obtained, a lanes of the road represented on the obtained road image is recognized, and a point of a road and lane in which the vehicle having the terminal arranged therein is detected. A virtual road image regarding the recognized lanes is generated, and the generated virtual lanes are added to the road image of the driving direction of the vehicle, and displayed. Traffic information for each lane and surrounding information (i.e. lane closure, construction, accident, etc.,) at the detected point of the relevant road are obtained, and the obtained information is displayed for each virtual lane.